Journal article
Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study
J Sarris, GJ Byrne, CA Bousman, L Cribb, KM Savage, O Holmes, J Murphy, P Macdonald, A Short, S Nazareth, E Jennings, SR Thomas, E Ogden, S Chamoli, A Scholey, C Stough
Australian and New Zealand Journal of Psychiatry | SAGE PUBLICATIONS LTD | Published : 2020
Abstract
Objective: Previous randomised, double-blind, placebo-controlled studies have shown that Kava (a South Pacific medicinal plant) reduced anxiety during short-term administration. The objective of this randomised, double-blind, placebo-controlled study was to perform a larger, longer-term trial assessing the efficacy and safety of Kava in the treatment of generalised anxiety disorder and to determine whether gamma-aminobutyric acid transporter (SLC6A1) single-nucleotide polymorphisms were moderators of response. Methods: The trial was a phase III, multi-site, two-arm, 16-week, randomised, double-blind, placebo-controlled study investigating an aqueous extract of dried Kava root administered tw..
View full abstractGrants
Awarded by Sanofi
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was funded by an Australian National Health and Medical Research Council (NHMRC) grant (No. APP1063383) and cofunded by Integria Healthcare (who were completely uninvolved in the study design, data analysis as well as write-up and editing of the results). J.S. was supported by an NHMRC Clinical Research Fellowship (No. APP1125000). The raw material used in the investigational tablets was sourced specifically for the trial and is different from that used in products currently marketed by Integria Healthcare.